Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe
Highlights: Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulatory and commercial benefits Positions Neurizon to advance the development of NUZ-001 for patients...
ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0.99%; and at...
Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases
HERLEV, Denmark, Nov. 11, 2024 /PRNewswire/ -- Nordic Bioscience, a leading biomarker company, announced that its CPa9-HNE biomarker assay received a Letter of Support (LoS) from the U.S. Food and Drug Administration (FDA). CPa9-HNE identifies true neutrophil activation, measured in the blood For the past thirty years, Nordic Bioscience has...
L’Oréal Showcases its Open Innovation Ecosystem Through Its Big Bang Beauty Tech Program at the 7th CIIE
Announcing North Asia BIG BANG Beauty Tech Innovation Program 2024 Winners and New Sustainability Track SHANGHAI, Nov. 11, 2024 /PRNewswire/ -- L'Oréal has reaffirmed its unwavering commitment to open innovation through its North Asia BIG BANG Beauty Tech Innovation Program (BIG BANG) at the 7th China International Import Expo (CIIE), announcing the 2024 winners across all 5 North Asia markets for...
Professor Narayanan Parameswaran’s team at Michigan State University announced that Red Ginseng is effective for intestinal health and preventing bone loss
JEJU, South Korea, Nov. 11, 2024 /PRNewswire/ -- Professor Narayanan Parameswaran's team at the Department of Physiology at Michigan State University announced the results of a study that showed that consuming red ginseng is effective for bone and intestinal health through intestinal microbiota balance at the Korea Ginseng Society International Conference held from October 27 (Sun) to 30 (Wed). ...
GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia
PISCATAWAY, N.J., Nov. 11, 2024 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript"), a global leader in life sciences services and products, has announced the establishment of new operations site and logistics center in Sydney, Australia. This strategic expansion represents a significant milestone in GenScript's continued commitment to supporting the rapid growth of the biotechnology sector in Australia. It also underscores...
TB Alliance Joins Indonesia’s High-Level Meeting on TB
Announces Strategy to Accelerate Efforts Toward Ending the TB Pandemic BALI, Indonesia, Nov. 11, 2024 /PRNewswire/ -- TB Alliance is honored to join today's High-Level Meeting hosted by the Indonesian Ministry of Health. Leaders and experts in tuberculosis (TB) have convened to discuss strategies, innovations, and achievements in the global fight to end TB. The full-day session will bring...
Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024
SUZHOU, China, Nov. 11, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint inhibitor, were presented for the first time as a poster in the Late-Breaking Abstract (LBA) session at the 39th Annual Meeting...
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen’s Hybrozyme™ Technology
DAEJEON, South Korea, Nov. 11, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ Technology, to develop and commercialize a subcutaneous version of ENHERTU® (fam-trastuzumab...
Welcome to 2024 Chinese Congress of Holistic Integrative Oncology (2024 CCHIO)& 4th International Congress of the Asian Oncology Society (AOS2024)
XI'AN, China, Nov. 9, 2024 /PRNewswire/ -- On behalf of the organizing committee of the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), we are very pleased to invite you to attend the 2024 CCHIO & 4th International Congress of the Asian Oncology Society (AOS2024) . This esteemed event will be held from November 14-16, 2024, in the historic...
